Repligen Corporation (RGEN): Price and Financial Metrics


Repligen Corporation (RGEN)

Today's Latest Price: $181.43 USD

2.28 (1.27%)

Updated Nov 25 4:00pm

Add RGEN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

RGEN Stock Summary

  • With a price/earnings ratio of 217.8, Repligen Corp P/E ratio is greater than that of about 96.42% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for Repligen Corp is higher than 97.12% of stocks in our set with a positive cash flow.
  • RGEN's price/sales ratio is 29.19; that's higher than the P/S ratio of 93.32% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Repligen Corp are SWI, OMCL, DT, VRNT, and GLOB.
  • Visit RGEN's SEC page to see the company's official filings. To visit the company's web site, go to www.repligen.com.

RGEN Stock Price Chart Interactive Chart >

Price chart for RGEN

RGEN Price/Volume Stats

Current price $181.43 52-week high $212.55
Prev. close $179.15 52-week low $78.41
Day low $178.54 Volume 259,700
Day high $183.75 Avg. volume 517,036
50-day MA $171.63 Dividend yield N/A
200-day MA $133.91 Market Cap 9.55B

Repligen Corporation (RGEN) Company Bio


Repligen Corporation develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company was founded in 1981 and is based in Waltham, Massachusetts.

RGEN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$181.43$18.82 -90%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Repligen Corp. To summarize, we found that Repligen Corp ranked in the 11th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Repligen Corp, consider:

  • The compound growth rate in the free cash flow of Repligen Corp over the past 5.64 years is 0.24%; that's higher than 58.76% of free cash flow generating stocks in the Healthcare sector.
  • 97% of the company's capital comes from equity, which is greater than 89.03% of stocks in our cash flow based forecasting set.
  • The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than merely 10.93% of the free cash flow producing stocks we're observing.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-90%
1%-90%
2%-90%
3%-90%
4%-90%
5%-90%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as RGEN, try BHC, VAR, QGEN, SIGA, and COO.


RGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

RGEN Latest Social Stream


Loading social stream, please wait...

View Full RGEN Social Stream

Latest RGEN News From Around the Web

Below are the latest news stories about Repligen Corp that investors may wish to consider to help them evaluate RGEN as an investment opportunity.

Repligen Corporation's (RGEN) CEO Tony Hunt on Q2 2020 Results - Earnings Call Transcript

Repligen Corporation (RGEN) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Financial Corp. Puneet Souda -...

SA Transcripts on Seeking Alpha | July 31, 2020

Repligen (RGEN) Hits Fresh High: Is There Still Room to Run?

Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Yahoo | July 31, 2020

Repligen Gaps Up On Earnings

Repligen's bioprocessing products are helping customers fast-track Coronavirus vaccines and therapies.

Yahoo | July 30, 2020

Repligen (RGEN) Q2 Earnings and Revenues Top Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 50.00% and 11.98%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 30, 2020

Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance

* Reports record quarterly revenue of $87.5 million * Overall revenue grew 24% year-over-year, with organic growth of 19% * Raises revenue guidance to $332-$340 million for full year 2020, representing 18%-21% organic growth * Completes acquisition of silicone molding and tubing manufacturer Engineered Molding TechnologyWALTHAM, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2020. Provided in this press release are financial highlights for the three- and six- month periods ended June 30, 2020, updates to our financial guidance for the fiscal year 2020 and access information for today’s webcast and conference call.Tony J. H...

Yahoo | July 30, 2020

Read More 'RGEN' Stories Here

RGEN Price Returns

1-mo 3.18%
3-mo 20.80%
6-mo 38.53%
1-year 101.84%
3-year 424.52%
5-year 526.48%
YTD 96.14%
2019 75.39%
2018 45.37%
2017 17.72%
2016 8.94%
2015 42.88%

Continue Researching RGEN

Want to see what other sources are saying about Repligen Corp's financials and stock price? Try the links below:

Repligen Corp (RGEN) Stock Price | Nasdaq
Repligen Corp (RGEN) Stock Quote, History and News - Yahoo Finance
Repligen Corp (RGEN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7742 seconds.